Navigation Links
BioMS Medical Announces Third Quarter 2009 Results
Date:11/12/2009

------------------------- --------------------------- --------------------------- Basic and diluted net income (loss) per common share 0.11 (0.01) 0.11 0.07 --------------------------- --------------------------- --------------------------- --------------------------- Basic weighted average number of common shares outstanding 91,009 91,261 91,009 91,112 --------------------------- --------------------------- --------------------------- --------------------------- Diluted weighted average number of common shares outstanding 91,009 91,261 91,009 91,919 --------------------------- --------------------------- --------------------------- --------------------------- BioMS Medical Corp Interim Consolidated Statements of Cash Flows (Unaudited) ------------------------------------------------------------------------- (expressed in thousands of Canadian dollars) Nine-month period ended Three-month period ended September 30, September 30, --------------------------- --------------------------- 2009 2008 2009 2008 $ $ $ $ Cash provided by (used in) Operating activities Net income (loss) 10,053 (774) 9,948 6,313 Items not involving cash Stock-based compensation 2,098 2,175 - 7 Amortization of licensing costs 736 1,103 - 368 Amortization of property and
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioMS Medical announces second quarter 2009 results
2. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
3. BioMS Medical to participate in panel session at Bio International Convention 2009
4. BioMS Medical Announces First quarter 2009 results
5. BioMS Medical to present at Alberta Economic Forum in Geneva
6. BioMS Medical to present at BioFinance 2009
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical Announces 2008 Year End Results
10. BioMS Medical warrant extension
11. BioMS Medical to present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Israel , September 2, 2015 ... the intent of the National Institute of Allergy and Infectious ... (NIH) within the Department of Health and Human Services (HHS), ... in the United States in the ... universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, ...
(Date:9/2/2015)... Whitehouse, NJ (PRWEB) , ... September 02, 2015 ... ... key Technical Services Staff members will be attending Pharma Ed Resources upcoming ... and respected group of industry leading speakers, this timely conference will provide Updates ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, a ... today unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery 2015. ... market a rich set of new capabilities. Screener now supports High Throughput Flow ...
(Date:9/1/2015)... Sept. 1, 2015 The American Brain Tumor ... for its Discovery Research Grant program. LOIs are due ... noon CDT. Discovery Grants are one-year, $50,000 ... potential to change current diagnostic or treatment paradigms for ... encourage novel research at its earliest stages, in the ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... Wilson , an 18-year GE veteran, was promoted to president ... May to replace Gregory Lucier, who left to become CEO ... most of GE Medical's monitoring systems . , ,It's a ... growth opportunity (GE Medical is about $9 billion and produced ...
... - With Sony set to take over Sonic Foundrys desktop ... go from here? Two words: Mediasite Live. , ,Sonic ... audio conferencing market by enhancing web conferencing with Mediasite Live. ... great opportunity for the company to go forward because there ...
... employee scheduling and management products. The company was the ... Suite Scheduler, a former nurse manager frustrated with the ... facility. , ,Suite Scheduler products are able to improve ... of the time to create and manage employee schedules ...
Cached Biology Technology:CEO Wilson Defines GE's Health-IT Customer 2CEO Wilson Defines GE's Health-IT Customer 3CEO Wilson Defines GE's Health-IT Customer 4Sonic Foundry: What's Next? 2Scheduling made easy with Suite Scheduler 2Scheduling made easy with Suite Scheduler 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... work, home or elsewhere results in a disproportionate rise ... University of Nottingham researchers have found. , A new ... Heart Association, measured the level of cotinine in participants' ... to second-hand smoke. Cotinine is the major metabolite of ...
... Trek: The Next Generation," Geordi La Forge is a ... special implants in his eyes. While the Star Trek ... the 21st century may not have to wait that ... a University of Missouri-Columbia veterinary ophthalmologist, has been working ...
... with a knowledge of the properties and actions of enzymes, ... anti-cancer drugs originally isolated from blue-green algae. , This ... of the promising drugs for use in clinical trials. ... January issue of the journal ACS Chemical Biology, a scientific ...
Cached Biology News:Indicators for risk of heart disease are higher in passive smokers 2Indicators for risk of heart disease are higher in passive smokers 3MU researcher placing eye implants in cats to help humans see 2Turning green gunk to gold, anti-cancer gold 2
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
...
Donor Goat Serum...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Biology Products: